New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) & Biogen Idec, Inc. (Massachusetts) Commitment to Improving Outcomes in Multiple Sclerosis

WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced findings from several studies of TYSABRI (natalizumab) evaluating its long-ter…
Read the full story: BioSpace.com Featured News